Anti-APOE Antibodies

2010

In this project, the researchers hypothesize that targeting apoE, a component of amyloid plaques, can result in less Aβ aggregation in the brain and decreased Aβ-related pathology and that this treatment will have fewer side effects than the use of anti-Aβ antibodies. The project will test this hypothesis in this proposal in the context of human apoE isoforms.


Funding to Date

$100,000

Focus

Foundational Genetics

Researchers

David Holtzman, M.D.